CYP21A2 |
Hyperandrogenism |
0.838712 |
5 |
TRUE |
Included in national screening panel |
1 |
1 |
0.935485 |
HBB |
Haemoglobin variant |
0.197344 |
17 |
TRUE |
Included in national screening panel |
0.918184 |
0.918184 |
0.629848 |
MEFV |
Neutrophilic dermatosis |
0.752691 |
3 |
TRUE |
Included in national screening panel |
0.542552 |
0.542552 |
0.626608 |
SGCG |
Muscular dystrophy, limb girdle |
1 |
1 |
TRUE |
Included in national screening panel |
0.236572 |
0.236572 |
0.541943 |
HBD |
Haemoglobin variant |
0.967746 |
1 |
TRUE |
Included in national screening panel |
0.229039 |
0.229039 |
0.524522 |
F2 |
Thrombophilia 1 due to thrombin defect |
0.677421 |
1 |
TRUE |
Included in national screening panel |
0.16094 |
0.16094 |
0.367532 |
ABCA4 |
Retinal dystrophy |
0.211982 |
7 |
TRUE |
Included in national screening panel |
0.397026 |
0.397026 |
0.323009 |
CUBN |
Albuminuria, association with |
0.17742 |
8 |
TRUE |
Included in national screening panel |
0.39329 |
0.39329 |
0.306942 |
HBA1 |
Haemoglobin variant |
0.333334 |
3 |
TRUE |
Included in national screening panel |
0.253599 |
0.253599 |
0.285493 |
ABCA12 |
Ichthyosis |
0.483872 |
1 |
TRUE |
Included in national screening panel |
0.115249 |
0.115249 |
0.262698 |
CD36 |
Platelet glycoprotein IV deficiency |
0.188172 |
6 |
TRUE |
Included in national screening panel |
0.30648 |
0.30648 |
0.259157 |
ITGB3 |
Bleeding disorder |
0.451614 |
1 |
TRUE |
Included in national screening panel |
0.107611 |
0.107611 |
0.245212 |
BCHE |
Butyrylcholinesterase deficiency |
0.27957 |
3 |
TRUE |
Included in national screening panel |
0.214307 |
0.214307 |
0.240412 |
DONSON |
Microcephaly |
0.338711 |
2 |
TRUE |
Included in national screening panel |
0.168675 |
0.168675 |
0.236689 |
HBA2 |
Haemoglobin variant |
0.322582 |
2 |
TRUE |
Included in national screening panel |
0.161698 |
0.161698 |
0.226051 |
CYP1B1 |
Glaucoma 3A |
0.258065 |
3 |
TRUE |
Included in national screening panel |
0.199576 |
0.199576 |
0.222972 |
PAH |
Hyperphenylalaninemia |
0.0537636 |
15 |
TRUE |
Included in national screening panel |
0.300884 |
0.300884 |
0.202036 |
GJB2 |
Keratoderma |
0.161291 |
5 |
TRUE |
Included in national screening panel |
0.223462 |
0.223462 |
0.198593 |
SORD |
Neuronopathy, distal hereditary motor, autosomal recessive 8 |
0.35484 |
1 |
TRUE |
Included in national screening panel |
0.0846583 |
0.0846583 |
0.192731 |
GALNT3 |
Tumoral calcinosis |
0.225807 |
2 |
TRUE |
Included in national screening panel |
0.11556 |
0.11556 |
0.159659 |
PKLR |
Pyruvate kinase deficiency |
0.161291 |
3 |
TRUE |
Included in national screening panel |
0.13081 |
0.13081 |
0.143002 |
MPL |
Thrombocytosis, association with |
0.258065 |
1 |
TRUE |
Included in national screening panel |
0.0616473 |
0.0616473 |
0.140214 |
F7 |
Factor VII deficiency |
0.112904 |
4 |
TRUE |
Included in national screening panel |
0.130816 |
0.130816 |
0.123651 |
COQ9 |
Primary coenzyme Q10 deficiency, neonatal onset |
0.225807 |
1 |
TRUE |
Included in national screening panel |
0.0539641 |
0.0539641 |
0.122701 |
NCF1 |
Chronic granulomatous disease |
0.225807 |
1 |
TRUE |
Included in national screening panel |
0.0539641 |
0.0539641 |
0.122701 |
SLC26A4 |
Deafness |
0.0903227 |
5 |
TRUE |
Included in national screening panel |
0.138933 |
0.138933 |
0.119489 |
AVIL |
Nephrotic syndrome |
0.193549 |
1 |
TRUE |
Included in national screening panel |
0.0462744 |
0.0462744 |
0.105184 |
PIGO |
PIGO deficiency |
0.193549 |
1 |
TRUE |
Included in national screening panel |
0.0462744 |
0.0462744 |
0.105184 |
UFSP2 |
?Hip dysplasia |
0.193549 |
1 |
TRUE |
Included in national screening panel |
0.0462744 |
0.0462744 |
0.105184 |
ALDH3A2 |
Sjogren-Larsson syndrome |
0.0887098 |
4 |
TRUE |
Included in national screening panel |
0.108123 |
0.108123 |
0.100357 |
KIF1C |
Cerebellar ataxia |
0.129032 |
2 |
TRUE |
Included in national screening panel |
0.0694861 |
0.0694861 |
0.0933046 |
HSPG2 |
Scoliosis, idiopathic, association with |
0.0806455 |
4 |
TRUE |
Included in national screening panel |
0.1002 |
0.1002 |
0.092378 |
TPO |
Thyroid dyshormonogenesis 2A |
0.0645164 |
5 |
TRUE |
Included in national screening panel |
0.107935 |
0.107935 |
0.0905674 |
AGK |
Sengers syndrome |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
C7 |
Alzheimer disease in Han Chinese, association with |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
C8A |
Complement C8 alpha-gamma deficiency |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
ORC6 |
Meier-Gorlin syndrome |
0.161291 |
1 |
TRUE |
Included in national screening panel |
0.0385782 |
0.0385782 |
0.0876631 |
RPGRIP1 |
Cone-rod dystrophy 13 |
0.0860216 |
3 |
TRUE |
Included in national screening panel |
0.0772147 |
0.0772147 |
0.0807375 |
EYS |
Retinitis pigmentosa |
0.0368664 |
7 |
TRUE |
Included in national screening panel |
0.108136 |
0.108136 |
0.0796279 |
BTD |
Biotinidase deficiency |
0.00992557 |
13 |
TRUE |
Included in national screening panel |
0.123722 |
0.123722 |
0.0782036 |
TYR |
Albinism, oculocutaneous |
0.0430108 |
6 |
TRUE |
Included in national screening panel |
0.100407 |
0.100407 |
0.0774485 |
UPB1 |
Beta-ureidopropionase deficiency |
0.075269 |
3 |
TRUE |
Included in national screening panel |
0.0694731 |
0.0694731 |
0.0717915 |
ABCG8 |
Sitosterolemia 1 |
0.0752689 |
3 |
TRUE |
Included in national screening panel |
0.0694342 |
0.0694342 |
0.0717681 |
CCDC40 |
Primary ciliary dyskinesia |
0.0967744 |
2 |
TRUE |
Included in national screening panel |
0.0540419 |
0.0540419 |
0.0711349 |
PCARE |
Retinitis pigmentosa 54 |
0.0967743 |
2 |
TRUE |
Included in national screening panel |
0.0540094 |
0.0540094 |
0.0711154 |
GLDC |
Glycine encephalopathy |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
GNE |
GNE myopathy |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
GP6 |
Absence of collagen-induced platelet activation |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
GRM6 |
Congenital stationary night blindness |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
PLOD1 |
Ehlers-Danlos syndrome |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
PSAP |
Combined SAP deficiency |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
PTPRQ |
Congenital sensorineural hearing loss, autosomal recessive |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
VDR |
Rickets |
0.129032 |
1 |
TRUE |
Included in national screening panel |
0.0308755 |
0.0308755 |
0.0701383 |
USH2A |
Retinitis Pigmentosa |
0.0201614 |
8 |
TRUE |
Included in national screening panel |
0.0927886 |
0.0927886 |
0.0637377 |
LAMA1 |
Schizophrenia |
0.0645162 |
3 |
TRUE |
Included in national screening panel |
0.0618028 |
0.0618028 |
0.0628882 |
ABCC6 |
Pseudoxanthoma elasticum |
0.0387097 |
5 |
TRUE |
Included in national screening panel |
0.0772147 |
0.0772147 |
0.0618127 |
RAB3GAP2 |
Microphthalmia & cataract |
0.0483872 |
4 |
TRUE |
Included in national screening panel |
0.0695574 |
0.0695574 |
0.0610893 |
COL17A1 |
Epithelial recurrent erosion dystrophy |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
GNRHR |
Hypogonadotropic hypogonadism |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
NR2E3 |
Retinitis pigmentosa 37 |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
RARS2 |
Pulmonary arterial hypertension |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463392 |
0.0463392 |
0.0600616 |
CCNO |
Ciliary dyskinesia |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463132 |
0.0463132 |
0.0600461 |
CDK5RAP2 |
Autism spectrum disorder |
0.0806453 |
2 |
TRUE |
Included in national screening panel |
0.0463132 |
0.0463132 |
0.0600461 |
CDH23 |
Usher syndrome |
0.0268818 |
6 |
TRUE |
Included in national screening panel |
0.0773185 |
0.0773185 |
0.0571438 |
VWF |
von Willebrand disease |
0.0403227 |
4 |
TRUE |
Included in national screening panel |
0.0618093 |
0.0618093 |
0.0532147 |
ALDOB |
Fructose intolerance |
0.0967743 |
1 |
TRUE |
Included in national screening panel |
0.0231663 |
0.0231663 |
0.0526095 |
CNGB3 |
Achromatopsia 3 |
0.0967743 |
1 |
TRUE |
Included in national screening panel |
0.0231663 |
0.0231663 |
0.0526095 |
PJVK |
Deafness |
0.0967743 |
1 |
TRUE |
Included in national screening panel |
0.0231663 |
0.0231663 |
0.0526095 |
GAA |
Glycogen storage disease II |
0.0215054 |
6 |
TRUE |
Included in national screening panel |
0.0695833 |
0.0695833 |
0.0503522 |
MYO5B |
Diarrhea 2 |
0.0645162 |
2 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0489884 |
SLC3A1 |
Cystinuria |
0.0645162 |
2 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0489884 |
ZFYVE26 |
Spastic paraplegia with thin corpus callosum |
0.0645162 |
2 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0489884 |
SLC12A3 |
Gitelman syndrome |
0.0322581 |
4 |
TRUE |
Included in national screening panel |
0.0541002 |
0.0541002 |
0.0453634 |
GYS2 |
Glycogen storage disease 0 |
0.0430109 |
3 |
TRUE |
Included in national screening panel |
0.0463781 |
0.0463781 |
0.0450312 |
GALC |
Krabbe disease |
0.0430108 |
3 |
TRUE |
Included in national screening panel |
0.0463651 |
0.0463651 |
0.0450234 |
SI |
Sucrase isomaltase deficiency |
0.0430108 |
3 |
TRUE |
Included in national screening panel |
0.0463651 |
0.0463651 |
0.0450234 |
CFTR |
Cystic fibrosis |
0.0193549 |
5 |
TRUE |
Included in national screening panel |
0.0541196 |
0.0541196 |
0.0402137 |
ACADS |
Short-chain acyl-CoA-dehydrogenase deficiency |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309144 |
0.0309144 |
0.0379035 |
SPG7 |
Spastic paraplegia |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309144 |
0.0309144 |
0.0379035 |
ANO5 |
Muscular dystrophy, limb girdle 2L |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309014 |
0.0309014 |
0.0378957 |
F11 |
Factor XI deficiency |
0.0483872 |
2 |
TRUE |
Included in national screening panel |
0.0309014 |
0.0309014 |
0.0378957 |
OBSL1 |
Cardiomyopathy, dilated |
0.0241936 |
4 |
TRUE |
Included in national screening panel |
0.0463911 |
0.0463911 |
0.0375121 |
TRIP4 |
Spinal muscular atrophy & congenital bone fractures |
0.0241936 |
4 |
TRUE |
Included in national screening panel |
0.0463911 |
0.0463911 |
0.0375121 |
TTC37 |
Fatigue, failure to thrive & diarrhoea |
0.0241936 |
4 |
TRUE |
Included in national screening panel |
0.0463911 |
0.0463911 |
0.0375121 |
DPYS |
Dihydropyrimidinase deficiency |
0.0107527 |
6 |
TRUE |
Included in national screening panel |
0.0541326 |
0.0541326 |
0.0367807 |
GCDH |
Glutaric acidaemia 1 |
0.0322581 |
3 |
TRUE |
Included in national screening panel |
0.0386495 |
0.0386495 |
0.0360929 |
TTC21B |
Bardet-Biedl syndrome |
0.0322581 |
3 |
TRUE |
Included in national screening panel |
0.0386495 |
0.0386495 |
0.0360929 |
TPRN |
Hearing loss |
0.0322581 |
3 |
TRUE |
Included in national screening panel |
0.0386365 |
0.0386365 |
0.0360851 |
APTX |
Ataxia |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
B3GALT6 |
Spondyloepimetaphyseal dysplasia with joint laxity |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
C8B |
Primary immunodeficiency disease |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
CERS3 |
Ichthyosis |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
CYP4V2 |
Retinitis pigmentosa |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
HSD11B2 |
Apparent mineralocorticoid excess |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
MOCOS |
Thiopurine-induced toxicity |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
MTRR |
Cleft lip with or without cleft palate |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
PEX6 |
Peroxisome biogenesis disorder 4B |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
PHC1 |
Primary microcephaly |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
PMM2 |
Congenital disorder of glycosylation 1a |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
PSAT1 |
Developmental disorder |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
SAG |
Retinitis pigmentosa, autosomal recessive |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
SBF1 |
Charcot-Marie-Tooth disease |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
SVBP |
Neurodevelopmental disorder with ataxia |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
TMEM107 |
Oral-facial-digital syndrome |
0.0645162 |
1 |
TRUE |
Included in national screening panel |
0.0154507 |
0.0154507 |
0.0350769 |
DNAH5 |
Primary ciliary dyskinesia |
0.0161291 |
4 |
TRUE |
Included in national screening panel |
0.0386559 |
0.0386559 |
0.0296452 |
ATP2A1 |
Autism spectrum disorder |
0.0215055 |
3 |
TRUE |
Included in national screening panel |
0.0309274 |
0.0309274 |
0.0271586 |
KCNJ1 |
Bartter syndrome |
0.0215055 |
3 |
TRUE |
Included in national screening panel |
0.0309274 |
0.0309274 |
0.0271586 |
CA5A |
Carbonic anhydrase VA deficiency |
0.0215054 |
3 |
TRUE |
Included in national screening panel |
0.0309209 |
0.0309209 |
0.0271547 |
DPYD |
Dihydropyrimidine dehydrogenase deficiency |
0.0215054 |
3 |
TRUE |
Included in national screening panel |
0.0309209 |
0.0309209 |
0.0271547 |
IL17RA |
IL-17RA deficiency with bacterial and fungal infections |
0.0215054 |
3 |
TRUE |
Included in national screening panel |
0.0309209 |
0.0309209 |
0.0271547 |
DNASE1L3 |
Systemic lupus erythematosus 16 |
0.0322582 |
2 |
TRUE |
Included in national screening panel |
0.0231923 |
0.0231923 |
0.0268187 |
PANK2 |
Neurodegeneration with brain iron accumulation 1 |
0.0322582 |
2 |
TRUE |
Included in national screening panel |
0.0231923 |
0.0231923 |
0.0268187 |
ADA2 |
Sneddon syndrome |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
B3GAT3 |
Multiple joint dislocations |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
CYP11B1 |
Steroid-11 beta-hydroxylase deficiency |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
FAH |
Tyrosinemia |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
SBDS |
Shwachman-Diamond syndrome |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
TMEM138 |
Joubert syndrome 16 |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
TMPRSS3 |
Hearing loss |
0.0322581 |
2 |
TRUE |
Included in national screening panel |
0.0231858 |
0.0231858 |
0.0268147 |
CNGA3 |
Achromatopsia 2 |
0.00645164 |
5 |
TRUE |
Included in national screening panel |
0.0386689 |
0.0386689 |
0.025782 |
TRIOBP |
Developmental disorder |
0.00645164 |
5 |
TRUE |
Included in national screening panel |
0.0386689 |
0.0386689 |
0.025782 |
ALMS1 |
Alstrom syndrome |
0 |
6 |
TRUE |
Included in national screening panel |
0.0386754 |
0.0386754 |
0.0232052 |
LOXHD1 |
Deafness |
0 |
6 |
TRUE |
Included in national screening panel |
0.0386754 |
0.0386754 |
0.0232052 |
ATM |
Ataxia-telangiectasia |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
CEP290 |
Leber congenital amaurosis 10 |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
DYNC2H1 |
Asphyxiating thoracic dystrophy |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
PKHD1 |
Polycystic kidney disease 4 |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
VPS13B |
Cohen syndrome |
0.00806455 |
4 |
TRUE |
Included in national screening panel |
0.0309338 |
0.0309338 |
0.0217861 |
DUOX2 |
Hypothyroidism |
0 |
5 |
TRUE |
Included in national screening panel |
0.0309403 |
0.0309403 |
0.0185642 |
AGXT |
Hyperoxaluria |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
ALPL |
Odontohypophosphatasia |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
ATP7B |
Wilson disease |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
C6 |
Inflammatory bowel disease, very early onset |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
CAPN3 |
Muscular dystrophy, limb girdle 2A |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
CPLANE1 |
Joubert syndrome |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
MVK |
Hyper-IgD syndrome |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
OTOGL |
Hearing impairment |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
PCDH15 |
Usher syndrome 1 |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
SPG11 |
Charcot-Marie-Tooth disease |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
SPTA1 |
Spherocytosis |
0.0107527 |
3 |
TRUE |
Included in national screening panel |
0.0231988 |
0.0231988 |
0.0182204 |
ACAD8 |
Isobutyryl-CoA dehydrogenase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
ACO2 |
Optic atrophy 9 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
AGRN |
Congenital myasthenic syndrome with distal muscle weakness & atrophy |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
AP4S1 |
Spastic paraplegia 52 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
ARSB |
Mucopolysaccharidosis type VI (Maroteaux-Lamy) |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
ASPM |
Microcephaly 5 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
ATP9A |
Neurodevelopmental disorder with poor growth and behavioral abnormalities |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
CFAP410 |
Retinitis pigmentosa |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
CHRNG |
Multiple pterygium syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
CNTN2 |
Hypogonadotropic hypogonadism |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
COL27A1 |
Steel syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
COL6A2 |
Bethlem myopathy 1 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
CRIPT |
Short stature, microcephaly & dysmorphic facies |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
DGAT1 |
Diarrhea |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
DGUOK |
Portal hypertension |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
DHODH |
Miller syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
DNAH9 |
Situs inversus and male infertility |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
DOCK6 |
Adams-Oliver syndrome 2 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
EDARADD |
Ectodermal dysplasia 11A |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
FANCC |
Fanconi anemia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
FRAS1 |
Congenital anomalies of the kidney and urinary tract |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
G6PC1 |
Glycogen storage disease Ia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
GALK1 |
Galactokinase deficiency, presenile cataract |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
GDAP1 |
Charcot-Marie-Tooth disease |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
GIPC3 |
Hearing loss, non-syndromic |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
IL12RB1 |
Mycobacterial infection |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
KIAA0586 |
Joubert syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
KLHL7 |
Retinitis pigmentosa 42 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
LAMA3 |
Epidermolysis bullosa, junctional |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
LHX3 |
Hypopituitarism and sensorineural hearing loss |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
LOXL3 |
Myopia 28 |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
LRPPRC |
Infantile mitochondrial disease, lethal |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
LRRK1 |
Osteosclerotic metaphyseal dysplasia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
MALT1 |
Immunodeficiency, combined |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
MCIDAS |
Ciliary dyskinesia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
MMACHC |
Methylmalonic aciduria and homocystinuria |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
ORC4 |
Lymphoproliferative disorder |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
OTOA |
Hearing loss |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
PEX1 |
Zellweger syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
PGM3 |
Fetal alcohol syndrome, predisposition to |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
PLA2G6 |
Infantile neuroaxonal dystrophy |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
PNPO |
Pyridoxamine 5'-phosphate oxidase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
POLG |
Mitochondrial recessive ataxia syndrome |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
QDPR |
Dihydropteridine reductase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
RAX |
Microphthalmia |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
SKIV2L |
Macular degeneration, age related, reduced risk |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
SLC5A7 |
Neuronopathy |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
SLC6A19 |
Hartnup disorder |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
TPI1 |
Hemolytic anemia due to triosephosphate isomerase deficiency |
0.0322582 |
1 |
TRUE |
Included in national screening panel |
0.00772861 |
0.00772861 |
0.0175404 |
ADAMTS18 |
Microcornea, myopic chorioretinal atrophy and telecanthus |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
AIRE |
Autoimmune polyendocrinopathy syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
ALDH7A1 |
Epilepsy |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
CDH3 |
Hypotrichosis |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
CFAP53 |
Dextrocardia and situs disturbances |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
CORO1A |
Haemophagocytic lymphohistiocytosis |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
EXPH5 |
Epidermolysis bullosa, junctional |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
FTCD |
Formiminoglutamic acidura |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
GAMT |
Cerebral creatine deficiency syndrome 2 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
GRHPR |
Hyperoxaluria II |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
IQCB1 |
Leber congenital amaurosis |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
LDLR |
LDL cholesterol level QTL2 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
LIFR |
Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
NPHS1 |
Nephrotic syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
OCLN |
Pseudo-TORCH syndrome 1 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
OTOG |
Hearing loss, sensorineural |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
PLEKHG5 |
Myopathy |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
PYGM |
McArdle disease |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
RNASEH2A |
Aicardi-Goutieres syndrome 4 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
ROGDI |
Kohlschütter-Tönz syndrome |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
SEC23B |
Anaemia, dyserythropoietic congenital, type II |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
SERPINF1 |
Osteogenesis imperfecta |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
SLC25A13 |
Intrahepatic cholestasis, neonatal |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
SLC34A1 |
?Fanconi renotubular syndrome 2 |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
TGM1 |
Ichthyosiform erythroderma, congenital, nonbullous |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
TRPM1 |
Night blindness |
0.0161291 |
2 |
TRUE |
Included in national screening panel |
0.0154637 |
0.0154637 |
0.0157299 |
GBA |
Gaucher disease |
0 |
4 |
TRUE |
Included in national screening panel |
0.0232052 |
0.0232052 |
0.0139231 |
PRG4 |
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome |
0 |
4 |
TRUE |
Included in national screening panel |
0.0232052 |
0.0232052 |
0.0139231 |
TMEM67 |
Nephronophthisis 11 |
0 |
4 |
TRUE |
Included in national screening panel |
0.0232052 |
0.0232052 |
0.0139231 |
ACADVL |
Very long chain acyl-CoA dehydrogenase deficiency |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
CLN3 |
Retinal dystrophy, early-onset |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
COL7A1 |
EBD |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
DNAH11 |
Ciliary dyskinesia |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
NBAS |
Bone, connective tissue, liver, immune system & retinal defects |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
OTOF |
Deafness, non-syndromic |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
PEPD |
Prolidase deficiency |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
RTTN |
Primary microcephaly & primordial dwarfism |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
STRC |
Deafness, non-syndromic |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
TTN |
Muscular dystrophy |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
TUBGCP6 |
Diaphragmatic hernia |
0 |
3 |
TRUE |
Included in national screening panel |
0.0154702 |
0.0154702 |
0.00928209 |
ACADSB |
Inborn error of metabolism |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
ADAMTS17 |
Weill-Marchesani syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
ADGRV1 |
Deafness, non-syndromic, autosomal recessive |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
AGL |
Glycogen storage disease 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
AHI1 |
Joubert syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
ALG1 |
Congenital disorder of glycosylation |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
ARSA |
Metachromatic leukodystrophy |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
CBS |
Homocystinuria |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
CCDC39 |
Primary ciliary dyskinesia |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
CTNS |
Cystinosis |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
CUL7 |
3-M syndrome 1 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
CYP27A1 |
Cerebrotendinous xanthomatosis |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
DOK7 |
Fetal akinesia deformation sequence 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
DYNC2I1 |
Short-rib thoracic dysplasia 8 with or without polydactyly |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
EVC2 |
Ellis-van Creveld syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
GBA2 |
Spastic paraplegia |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
GPR179 |
Autism spectrum disorder |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
HEXA |
[Hex A pseudodeficiency] |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
HGD |
Alkaptonuria |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
HGSNAT |
Mucopolysaccharidosis type IIIC (Sanfilippo C) |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
HPS3 |
Hermansky-Pudlak syndrome 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
IDUA |
Hurler syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
INPP5E |
Joubert syndrome 1 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
JAK3 |
Immunodeficiency, severe combined |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
LINS1 |
Intellectual developmental disorder |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
LYST |
Chediak-Higashi syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
MKS1 |
Parkinson disease, early onset |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
MYO15A |
Deafness, non-syndromic, autosomal recessive |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
NPHP1 |
Nephronophthisis 1 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
NPHP4 |
Nephronophthisis 4 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
PROC |
Thrombophilia 3 due to protein C deficiency |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
PTS |
Tetrahydrobiopterin deficiency |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
RAPSN |
Congenital myasthenic syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
RYR1 |
Congenital myopathy 1B |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
SACS |
Spastic ataxia, Charlevoix-Saguenay |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
SCN4A |
Paramyotonia congenita |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
SERPINA1 |
Reduced alpha-1-antitrypsin concentration |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
SLC25A20 |
Carnitine-acylcarnitine translocase deficiency |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
SLC37A4 |
Glycogen storage disease 1b |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
SPATA7 |
Leber congenital amaurosis 3 |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
THOC6 |
Intellectual disability |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
TMEM231 |
Meckel syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
UBR1 |
Johanson-Blizzard syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
WRN |
Werner syndrome |
0 |
2 |
TRUE |
Included in national screening panel |
0.00773508 |
0.00773508 |
0.00464105 |
ABAT |
GABA-transaminase deficiency |
0 |
1 |
NAN |
- |
0 |
0 |
0 |
ABCC8 |
Hyperinsulinism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ACADM |
Acyl-CoA dehydrogenase |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ADA |
Adenosine deaminase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ADAMTS13 |
Reduced expression |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
AIPL1 |
Leber congenital amaurosis IV |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
AKR1D1 |
Bile acid synthesis defect |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ALG2 |
Congenital disorder of glycosylation 1i |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ALG3 |
Congenital disorder of glycosylation |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ALG8 |
Congenital disorder of glycosylation 1h |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ANO10 |
Cerebellar ataxia 3 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ANTXR2 |
Hyaline fibromatosis syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ASAH1 |
Spinal muscular atrophy with progressive myoclonic epilepsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ASL |
Argininosuccinic aciduria |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ATP13A2 |
Kufor-Rakeb syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ATR |
Pulmonary fibrosis / aplastic anaemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
B3GALNT2 |
Muscular dystrophy-dystroglycanopathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
B3GLCT |
Peters-Plus syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
B4GALNT1 |
Spastic paraplegia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
BBS5 |
Phenotype modifier |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
BBS7 |
Bardet-Biedl syndrome, modifier of |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
BBS9 |
Retinitis pigmentosa |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
BCS1L |
GRACILE syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
BLM |
Breast cancer |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
C2CD3 |
Autism spectrum disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
C5 |
Complement C5 deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CABP4 |
Retinal dystrophy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CCDC103 |
Primary ciliary dyskinesia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CCN6 |
Pseudorheumatoid dysplasia, progressive |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CENPJ |
Intellectual disability |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CEP152 |
Seckel syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CHRNE |
Congenital myasthenic syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CLCNKB |
Bartter syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CLMP |
Congenital short-bowel syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CNTNAP1 |
Hypomyelinating neuropathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
COG7 |
Schizophrenia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
COL18A1 |
Knobloch syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
COX15 |
Hypertrophic cardiomyopathy, early onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
COX20 |
Dysarthria, ataxia and sensory neuropathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CRB1 |
Leber congenital amaurosis 8 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CRB2 |
Congenital nephrosis, Finnish type-like, with cerebral ventriculomegaly & raised alpha-fetoprotein |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
CTSK |
Pycnodysostosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
DARS2 |
Leukoencephalopathy with brainstem & spinal cord involvement |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
DLL3 |
Congenital scoliosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
DNAAF1 |
Neural tube defects |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
DOCK8 |
Immunodeficiency, primary |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
DPAGT1 |
Congenital disorder of glycosylation 1 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
DSP |
Cardiomyopathy, arrhythmogenic right ventricular |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ECEL1 |
Arthrogryposis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ECHS1 |
Short-chain enoyl-CoA hydratase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ELP1 |
Autism spectrum disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
EPG5 |
Vici syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ERCC2 |
Basal cell carcinoma, reduced risk, association with |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ESPN |
Hearing loss |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
EXOSC3 |
Pontocerebellar hypoplasia 1 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FA2H |
Spastic paraplegia 35 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FAM161A |
Retinitis pigmentosa |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FBP1 |
Fructose-1,6-bisphosphatase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FBXO7 |
Parkinsonism, juvenile |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FH |
Multiple leiomyomatosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FIG4 |
Amyotrophic lateral sclerosis, sporadic |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FLVCR1 |
Posterior column ataxia & retinitis pigmentosa |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FOXRED1 |
Complex I deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
FRRS1L |
Intellectual disability, developmental delay & seizures |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GALNS |
Mucopolysaccharidosis IVA |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GBE1 |
Glycogen storage disease 4 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GFPT1 |
Congenital myasthenic syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GHR |
Hypogonadotropic hypogonadism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GLB1 |
GM1-gangliosidosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GNPTAB |
Mucolipidosis III alpha/beta |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
GPHN |
Hyperekplexia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
HADHB |
Mitochondrial trifunctional protein deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
HSD17B3 |
Pseudohermaphroditism, male |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
HSD17B4 |
D-bifunctional protein deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
IFT140 |
Leber congenital amaurosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ITGB2 |
Leukocyte adhesion deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ITGB4 |
Hirschsprung disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
IVD |
Isovaleric acidemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
IYD |
Hypothyroidism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
KCNV2 |
Retinal cone dystrophy 3B |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
KIF7 |
Macrocephaly, multiple epiphyseal dysplasia & facial features |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LAMB2 |
Pierson syndrome/ nephrotic syndrome type 5 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LAMC2 |
Epidermolysis bullosa, Herlitz |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LIG4 |
Marfan syndrome, early-onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LMAN1 |
Factor V and factor VIII deficiency, combined |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LMBR1 |
Triphalangeal thumbs and preaxial polydactyly |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LMNA |
Mandibuloacral dysplasia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
LPL |
Hyperlipidaemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
MAPKBP1 |
Nephronophthisis, late onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
MMADHC |
Homocystinuria, cblD type |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
MMUT |
Methylmalonic aciduria |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
MPLKIP |
Trichothiodystrophy, nonphotosensitive |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
MPV17 |
Mitochondrial DNA depletion syndrome, hepatocerebral |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
MRE11 |
Breast cancer |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NBN |
Breast cancer, male |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NCF2 |
Chronic granulomatous disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NDUFAF5 |
Leigh syndrome/Mitochondrial Complex I deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NDUFS1 |
Neurodevelopmental disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NEK1 |
Amyotrophic lateral sclerosis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NEK8 |
Renal disease with hepatic and cardiac anomalies |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NKX6-2 |
Spastic ataxia 8 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
NUBPL |
Complex I deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
OPA1 |
Optic atrophy plus syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PC |
Hyperinsulinism |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PCCB |
Propionicacidemia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PDE6B |
Retinitis pigmentosa, pericentral |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PDP1 |
Tourette syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PEX12 |
Peroxisome biogenesis disorder 3B |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PEX16 |
Peroxisome biogenesis disorder 8B |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PEX26 |
Refsum disease, infantile |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PGM1 |
Congenital disorder of glycosylation |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PHGDH |
Neu-Laxova syndrome 1 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PNP |
Nucleoside phosphorylase deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
POR |
Altered function |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PRICKLE1 |
Neural tube defects |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PRUNE1 |
Hypotonia, microcephaly and global developmental delay |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
PYGL |
Glycogen storage disease 6 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
QARS1 |
Microcephaly |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
RAG1 |
Omenn syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
RECQL4 |
Baller-Gerold syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
RFXANK |
MHC class II deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
RNASEH2B |
Aicardi-Goutières syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
RNASEH2C |
Aicardi-Goutieres syndrome 3 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
ROBO3 |
Gaze palsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SCN9A |
Childhood absence epilepsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SEPSECS |
Cerebellar atrophy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SGCD |
Muscular dystrophy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SGSH |
Mucopolysaccharidosis type IIIA (Sanfilippo A) |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC19A3 |
Wernicke's-like encephalopathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC22A5 |
Carnitine deficiency |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC25A19 |
Thiamine metabolism dysfunction syndrome 4 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC2A1 |
Glucose transporter type 1 deficiency syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC35D1 |
Schneckenbecken dysplasia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC38A8 |
Foveal hypoplasia, optic nerve decussation defects and anterior segment dysgenesis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SLC39A14 |
?Hyperostosis cranalis interna |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
SMPD1 |
Niemann-Pick disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TMC1 |
Deafness |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TMCO1 |
Cerebro-facio-thoracic dysplasia |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TMEM237 |
Joubert syndrome related disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TRAPPC9 |
Hypogonadotropic hypogonadism, normosmic |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TRMT10A |
Neurodevelopmental disorder |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TSEN54 |
Intellectual disability & epilepsy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
TTC7A |
Immunodeficiency, combined, with intestinal atresias |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
VARS2 |
Mitochondrial encephalopathy |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
VPS33B |
Arthrogryposis, renal dysfunction and cholestasis |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
VPS53 |
Parkinson disease, early onset |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
WDR35 |
Short rib-polydactyly syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
WDR62 |
Microcephaly, primary |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
WHRN |
Usher syndrome |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
XPNPEP3 |
NPHP-like kidney disease |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |
XYLT1 |
Desbuquois dysplasia 2 |
0 |
1 |
TRUE |
Included in national screening panel |
0 |
0 |
0 |